Clinical trials: Adults
Fatigue
To Study the Effect of Investigational Product on Fatigue and Cardiorespiratory Fitness in Healthy Adults.
E-OJ-01 (Oxyjun®), a proprietary, standardized aqueous extract of TA, has been proven to improve cardiac output and thereby lead to better oxygenation capacity and exercise endurance.
- Trial name
- NCT05621395
- Testing
- E-OJ-01, Microcrystalline cellulose
- Where
- 4 sites in India
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Tetanus, Diphtheria
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults
The purpose of this study is to evaluate safety and efficacy (immunogenicity) of a single dose of GC3111 versus Boostrix® vaccine among healthy adults in 19-64 years of age.
- Conditions
- Tetanus, Diphtheria, Whooping Cough
- Trial name
- NCT04238975
- Testing
- GC3111 vaccine, Boostrix® vaccine
- Where
- South Korea
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Upper Respiratory Tract Infection
A Study to Evaluate the Efficacy of EQ-778 on Upper Respiratory Tract Health Status in Healthy Adults
This study is a randomized, double-blind, Placebo Controlled study to evaluate the efficacy of 180 days administration of EQ-778 on upper respiratory tract health status in healthy adults
- Trial name
- NCT05835375
- Testing
- EQ-778
- Where
- 13 sites in India
- Volunteers
- 374 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Muscular Dystrophy, Duchenne
Safety Study of BLS-M22 in Healthy Volunteers
BLS-M22 is being developed as an anti-myostatin agent for the treatment of Duchenne Muscular Dystrophy (Muscular Dystrophy). A total of 37 subjects participated in this study to confirm the safety of BLS-M22.
- Trial name
- NCT03789734
- Testing
- BLS-M22
- Where
- South Korea
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- BioLeaders Corporation
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 08/09 Season.
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT00665509
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Solvay Biologicals
Infection, Human Immunodeficiency Virus
A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects
In this study, approximately 16 subjects will receive raltegravir 400mg twice daily for 5 days (Treatment A) followed by a washout period. In Period 2, subjects will receive GSK2248761 200mg once daily for 5 days (Treatment B).
- Trial name
- NCT01101893
- Testing
- Raltegravir, GSK2248761, GSK2248761 + Raltegravir
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Pediatric Growth Hormone Deficiency (PGHD)
A Clinical Trail to Compare Pharmacokinetics of Two PEG-rhGH Injections With Different Preparations
The purpose of this study is to compare the pharmacokinetics of the two different PEG-rhGH preparations after a single administration.
- Trial name
- NCT06135168
- Testing
- PEG-rhGH with new preparation, PEG-rhGH with present preparation
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults
This study is designed to test the immunogenicity in terms of Hemagglutination Inhibition (HI) antibodies against each of the three vaccine influenza strains and reactogenicity and safety of Fluviral® containing the influenza…
- Trial name
- NCT01626820
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-04427429 administered intravenously to healthy adult volunteers.
- Trial name
- NCT01011296
- Testing
- PF-04427429
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Booster Study of SpikoGen COVID-19 Vaccine
The purpose of the study is to assess the effectiveness of Spikogen vaccine when used as a 3rd or 4th dose booster in adults who have been previously vaccinated with any Covid-19 vaccine types, including mRNA vaccine, adenoviral…
- Trial name
- NCT05542862
- Testing
- SpikoGen vaccine
- Where
- Australia
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Orthomyxoviridae Infection, Influenza
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Compared to young adults, the elderly mount a lower antibody response to vaccination. Thus, improvement of the immune response to influenza vaccination in this age group, which is at higher risk for influenza-related morbidity…
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00391053
- Testing
- High-Dose Inactivated, Split-Virion Influenza Vaccine, Inactivated, Split-Virion Influenza Vaccine
- Where
- 28 sites in United States
- Volunteers
- 3,851 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy
A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older
The purpose of this study for: Cohort 1 and Cohort 2: to assess the safety and reactogenicity of the intramuscular one- and two-dose regimens, with a booster at Month 12 (Cohort 1) and to select a regimen for Cohort 3.
- Trial name
- NCT03502707
- Testing
- RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp
- Where
- 6 sites in United States
- Volunteers
- 669 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Hyperlipidemia
A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers
The purpose of this study is to compare the pharmacokinetics and safety of a controlled release (CR) version of pitavastatin (also referred to as NK-104) to immediate release (IR) pitavastatin in healthy adult volunteers.
- Trial name
- NCT02634034
- Testing
- A: NK-104-CR 8 mg, B: Pitavastatin IR 4 mg, C: Pitavastatin IR 8 mg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Healthy Adult Subjects
A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
To evaluate the pharmacokinetics of single and multiple doses of pegilodecakin in healthy participants.
- Trial name
- Willow 1 (NCT03267732)
- Testing
- Pegilodecakin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hypertension
Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine and Losartan in Health Volunteers
The purpose of this study is to evaluate the comparative bioavailability of two fixed dose combination tablet formulations of amlodipine and losartan in healthy volunteers.
- Trial name
- NCT01648231
- Testing
- Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state, Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state, Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
- Where
- Australia
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Chronic Hepatitis B
A Study to Evaluate the Mass Balance Absorption and AME of VBR
This Phase 1 Study will determine the mass balance recovery, absorption, metabolism, and excretion of [14C] Vebicorvir in healthy male subjects
- Trial name
- NCT04637139
- Testing
- Vebicorvir (VBR)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Malaria
A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
The purpose of this study is to assess the antimalarial activity, pharmacokinetics, and safety of MK-7602 in healthy adults following Plasmodium falciparum (P. falciparum) infection.
- Trial name
- NCT06294912
- Testing
- Plasmodium falciparum, MK-7602, Artemether/lumefantrine
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Malaria (Plasmodium Falciparum)
Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults
This is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine) that will assess field efficacy in Africa.
- Trial name
- BFSPZL2 (NCT07385287)
- Testing
- Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride)
- Where
- Burkina Faso
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Healthy Volunteers
Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers
The study will be conducted in adult healthy participants and will consist of two phases: Prerandomization and Randomization. The Prerandomization Phase will consist of 2 periods: a Screening Period and a Baseline Period.
- Trial name
- NCT02792829
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.